# An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma

> **NCT05251948** · PHASE1,PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 40 (actual)

## Conditions studied

- Gastric and Gastroesophageal Junction Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Tiragolumab

## Key facts

- **NCT ID:** NCT05251948
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-01
- **Primary completion:** 2025-09-04
- **Final completion:** 2025-09-04
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Study was closed early as the sponsor decided not to continue development of certain treatment combinations.
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05251948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05251948, "An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05251948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*